Boston Common Asset Management LLC cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,379 shares of the biopharmaceutical company’s stock after selling 2,186 shares during the quarter. Boston Common Asset Management LLC’s holdings in Gilead Sciences were worth $4,132,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Penserra Capital Management LLC boosted its position in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares in the last quarter. American Beacon Advisors Inc. purchased a new position in Gilead Sciences during the first quarter valued at $143,000. Harel Insurance Investments & Financial Services Ltd. raised its stake in Gilead Sciences by 29.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 480 shares during the last quarter. Capstone Investment Advisors Netherlands B.V. purchased a new position in Gilead Sciences during the second quarter valued at $172,000. Finally, Sterling Investment Advisors Ltd. purchased a new position in Gilead Sciences during the second quarter valued at $184,000. Institutional investors own 76.23% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ GILD) opened at $73.29 on Thursday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $95,736.46, a price-to-earnings ratio of 7.65, a PEG ratio of -1.23 and a beta of 1.13.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.84%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.69%.
In related news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.56, for a total value of $6,054,372.48. The disclosure for this sale can be found here. Insiders sold 494,999 shares of company stock valued at $37,404,139 in the last ninety days. 1.30% of the stock is currently owned by corporate insiders.
A number of brokerages have issued reports on GILD. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Vetr cut Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective for the company. in a research note on Monday, September 4th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $83.00 price objective (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $85.22.
ILLEGAL ACTIVITY NOTICE: “Boston Common Asset Management LLC Reduces Position in Gilead Sciences, Inc. (GILD)” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3078934/boston-common-asset-management-llc-reduces-position-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.